A Randomized, Open Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine co-Administered Intramuscularly With Boostrix and/or Menactra in Healthy Female Subjects Aged 11–18 Years.

Trial Profile

A Randomized, Open Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine co-Administered Intramuscularly With Boostrix and/or Menactra in Healthy Female Subjects Aged 11–18 Years.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Dec 2016

At a glance

  • Drugs DTaP vaccine (Primary) ; Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate
  • Indications Cervical cancer; Diphtheria; Human papillomavirus infections; Pertussis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 03 Aug 2011 Primary endpoints 'Geometric-mean-antibody-concentration' , 'Geometric-mean-antibody-titre' and 'antibody levels' have been met.
    • 13 Oct 2009 Actual patient number (1330) added as reported by ClinicalTrials.gov.
    • 13 Oct 2009 Actual end date changed from Mar 2008 to Feb 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top